Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL

NCT01449344 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

128

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Rituximab
DRUG: High dose Ara-C
DRUG: Dexamethasone
DRUG: Bortezomib

Sponsor

Prof. Dr. M. Dreyling (co-chairman)

Collaborators

[object Object]
[object Object]
[object Object]